<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951132</url>
  </required_header>
  <id_info>
    <org_study_id>AHUSPP0651</org_study_id>
    <nct_id>NCT00951132</nct_id>
  </id_info>
  <brief_title>Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy</brief_title>
  <acronym>DECAMERONE</acronym>
  <official_title>Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether rosuvastatin decreases measures of
      inflammation in depressive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is associated with increased risk of cardiovascular disease, in which one possible
      mechanism is systemic inflammation. Further, patients at high risk of cardiovascular disease,
      rosuvastatin decreases the risk, especially among patients with increased inflammation. This
      is a proof-of-concept study to investigate whether the antiinflammatory effect of
      rosuvastatin is similar in depressive as in patients with cardiovascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean SUV of large arteries</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral endothelial function (pulse wave amplitude)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulatory proinflammatory markers</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>10mg tablets, once daily in three months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, once daily, three months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persisting self-reported depressive symptoms &gt; 5 weeks

          -  Indications of aortic atherosclerosis on PET/CT

        Exclusion Criteria:

          -  Clinical indication of statin use.

          -  Contraindication of statins, or of PET/CT and MRI.

          -  Established cardiovascular disease.

          -  Bipolar disorder og comorbid psychosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torbjorn Omland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunnar Einvik, MD</last_name>
    <phone>41104542</phone>
    <phone_ext>+47</phone_ext>
    <email>gunnar.einvik@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Torbjorn Omland, PhD</last_name>
    <phone>67968856</phone>
    <phone_ext>+47</phone_ext>
    <email>torbjorn.omland@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lorenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Einvik, MD</last_name>
      <phone>41104542</phone>
      <phone_ext>+47</phone_ext>
      <email>gunnar.einvik@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Torbjorn Omland</name_title>
    <organization>Akershus University Hospital</organization>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

